IPI Spring 2020

Page 68

Technology

Electronic Laboratory Notebooks: Addressing Data Security and Privacy Concerns From 21 CFR Part 11 to GDPR: Evolving Standards for Managing Data With the introduction of 21 CFR Part 11 in 1997, research laboratories and their software providers have been under an increasing burden to provide proof that data captured electronically is managed in an immutable fashion. Records must provide a complete pedigree from the original state through each edit, including who made the changes, what the changes were, and the date of each change. As GDPR impacts laboratorybased software, this audit trail must be preserved while maintaining compliance with a complex set of new data privacy requirements. These two contrasting requirements are also challenged by the changing landscape of drug discovery and development. The concept of a single company managing the complete life cycle of new drug development has been replaced with an ecosystem of partner networks that change as drugs move through the development pipeline. The ability to share data and collaborate in real time creates new challenges in information security, data integrity and identity management. This change in paradigm is magnified by the changing demographics of scientists within the lab. With each passing year, scientists are expecting their user experience within these complex enterprise tools to be comparable with the experience they get using consumer applications like Facebook or banking applications on their mobile platforms.

It is important for software providers to manage each of these challenges and provide innovative solutions to maintain market position, or open new lines of business, in this new reality. Each aspect of data management must be individually considered to ensure each aspect involved in a data management platform. These “separations of concern” include data capture and preservation, security, privacy and user experience while considering both regulatory compliance and product usability. Separations of Concern to Meet Regulatory and Business Requirements Designing an enterprise data system in a highly regulated market requires satisfying several sets of regulatory and IT requirements, including: 66 INTERNATIONAL PHARMACEUTICAL INDUSTRY

Spring 2020 Volume 12 Issue 1


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

How Advancements in Logistics Technology will Play a Role in Combating COVID-19

7min
pages 96-99

Generic Solid Oral Immediate Release Products in EU Regulatory Perspectives Dissolution Specification

21min
pages 78-85

User Testing: Critical for Truly Understanding

8min
pages 86-87

New Tools and Models Designed to Optimise Costs

7min
pages 94-95

Automated Quality Systems in Supply Chains

11min
pages 90-93

Q&A with Brussels Airport, Changi Airport

9min
pages 88-89

Help Your Tablet Tooling to Pack a Punch with

12min
pages 74-77

The Electronic Laboratory Notebooks: Addressing

11min
pages 68-73

Cardiac Imaging in Clinical Development: The

13min
pages 64-67

Why Connected Data is Crucial to Pharmaceutical Research

9min
pages 58-61

Caregivers in Oncology: How to Address the Needs

7min
pages 52-53

Proveris by Design: A Roadmap for In Vitro Characterisation of Combination Products

14min
pages 46-51

Taking Charge of the Clinical Trial Master File

8min
pages 62-63

Study Oversight Models & Implementation in Clinical Trials

9min
pages 54-57

Manufacturing Dpis: An Engineering Perspective (A Case Study)

7min
pages 42-45

Five Questions You Should Ask when Developing an

10min
pages 38-41

Rethinking Inhaler Systems from a Patient Perspective The Increasing Challenge of Technology Diversity

12min
pages 34-37

Driving R&D Towards 2030 – Waging War on Carbon

10min
pages 16-19

Challenges of Drug Development in Progressive Multiple Sclerosis

15min
pages 28-31

The Future Market Dynamics and Opportunities in Immune Oncology

11min
pages 20-23

Understanding the Health Dimensions of the Climate Crisis

10min
pages 24-27

Editor’s Letter

7min
pages 8-11

Enabling Competitive Entry: The Role of Drug Delivery Device Design in the Biosimilars Market

8min
pages 32-33

Excessive Prices in The Pharma Sector: The EU Antitrust Perspective

11min
pages 12-15
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.
IPI Spring 2020 by Senglobal - Issuu